- Review: found
Review of 'Apolipoprotein C-III's role in cardiovascular diseases, a short review.'
2014-12-18
Ilias Doulamis2
An interesting brief review regarding ApoC-III, but written in poor language and not well justified.
Average rating: | Rated 2 of 5. |
Level of importance: | Rated 2 of 5. |
Level of validity: | Rated 3 of 5. |
Level of completeness: | Rated 2 of 5. |
Level of comprehensibility: | Rated 1 of 5. |
Competing interests: | None |
Reviewed article
- Record: found
- Abstract: found
- Article: found
Apolipoprotein C-III's role in cardiovascular diseases, a short review.
Olteanu Emilian (2014)
Review information
| Keywords: | ApoC-III, CVD, Hypertriglyceridemia, Mutations |
Review text
In this article, Dr Olteanu presents a short overview of the available literature on the role of ApoC-III in CVD. The author also offers insight in the metabolic pathways and the mutations of ApoC-III and remarks their clinical impact. It is a useful mini review, since it refers to a marker that is not measured in everyday clinical practice, but it is accompanied with significant clinical manifestations regarding CVD. However, I feel that there are several concerns that need to be taken into consideration. These are the following:
Major Concerns
The entire manuscript needs to be re-organized and re-written due to several serious errors in composition, syntax and grammar. Moreover, it is also recommended that it is thoroughly edited by a scientific writer/editor.
The author concludes that ApoC-III could be a potential target for a number of novel drugs. However, drugs such as statins, fibrates, ezetimibe, etc that are reported to be related with lower levels of ApoC-III are not mentioned in the “discussion” section.
In order to elucidate the role of ApoC-III in CVD, there are more to be mentioned than just ApoC-III mutations. There are several clinical studies that report correlation between ApoC-III and cardiovascular events which deserve to be highlighted.
Apart from VLDL and LPL, ApoC-III also interacts with β-integrin, ICAM-I, VCAM-I. These molecules also play a significant role in CVD progression. Thus, they should not be omitted.
Minor Concerns
The article title could be changed to “Apolipoprotein C-III’s role in cardiovascular diseases: A brief review”.
In “ApoC-III SUMMARY” please specify which enteric cells participate in the excretion of ApoC-III.
Moreover, a more extensive review that sheds light on various aspects of the link between ApoC-III and CVD is the following “OOI et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clinical Science 2008;114:611-624”. Thus, it is my firm belief that it should be included in the references.
Major Concerns
The entire manuscript needs to be re-organized and re-written due to several serious errors in composition, syntax and grammar. Moreover, it is also recommended that it is thoroughly edited by a scientific writer/editor.
The author concludes that ApoC-III could be a potential target for a number of novel drugs. However, drugs such as statins, fibrates, ezetimibe, etc that are reported to be related with lower levels of ApoC-III are not mentioned in the “discussion” section.
In order to elucidate the role of ApoC-III in CVD, there are more to be mentioned than just ApoC-III mutations. There are several clinical studies that report correlation between ApoC-III and cardiovascular events which deserve to be highlighted.
Apart from VLDL and LPL, ApoC-III also interacts with β-integrin, ICAM-I, VCAM-I. These molecules also play a significant role in CVD progression. Thus, they should not be omitted.
Minor Concerns
The article title could be changed to “Apolipoprotein C-III’s role in cardiovascular diseases: A brief review”.
In “ApoC-III SUMMARY” please specify which enteric cells participate in the excretion of ApoC-III.
Moreover, a more extensive review that sheds light on various aspects of the link between ApoC-III and CVD is the following “OOI et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clinical Science 2008;114:611-624”. Thus, it is my firm belief that it should be included in the references.